Bayer Launches Phase IIa Trial for Alport Syndrome Treatment

Bayer has announced the initiation of a Phase IIa clinical trial for its investigational drug, BAY 3401016, aimed at treating patients with Alport Syndrome, a rare genetic disorder affecting kidney function. This first-in-patient study, named the ASSESS trial, is designed to evaluate the efficacy and safety of BAY 3401016 in adult participants diagnosed with the condition. The trial is registered under NCT07211685 and features a randomized, double-blind, placebo-controlled design.

Trial Details and Objectives

The ASSESS trial seeks to understand how well BAY 3401016 can slow the progression of kidney damage in adults experiencing rapid disease advancement. This investigational drug works by blocking the protein Semaphorin 3A (Sema3A), which is believed to play a role in the deterioration of kidney function associated with Alport Syndrome. According to Dr. Andrea Haegebarth, Global Head of Research and Early Development for Cardiovascular, Renal, and Immunology at Bayer’s Pharmaceuticals Division, this trial marks a significant milestone in their research efforts.

“We are collaborating closely with the patient organization community to gain a deeper understanding of the real challenges faced by people living with Alport Syndrome,” Dr. Haegebarth stated. “We believe BAY 3401016 holds promise as a potential therapeutic approach, and we look forward to assessing its efficacy and safety profile as we advance this important program in our pipeline.”

Currently, there are no approved specific treatments for Alport Syndrome. Patients often experience a progressive decline in kidney function, leading to end-stage kidney disease by their fourth decade of life or even sooner. The main goal of the ongoing study is to determine whether BAY 3401016 can effectively slow down the loss of kidney function in this population.

Understanding Alport Syndrome

Alport Syndrome is caused by genetic mutations affecting type IV collagen, a critical component in the structure of kidneys, ears, and eyes. The condition leads to severe proteinuria and progressive loss of kidney function, increasing the risk of chronic kidney disease (CKD). Diagnosis can occur in childhood or adulthood, depending on the specific genetic mutation. Despite the absence of specific treatments, patients may undergo guideline-recommended therapies, yet they often still face a decline in kidney function.

Individuals with Alport Syndrome may experience a range of symptoms, with women often presenting milder symptoms initially before facing later onset disease progression. The presence of albumin in urine is a common indicator of impaired kidney function, often leading to further assessment through urine tests, kidney biopsies, or genetic testing.

BAY 3401016, derived from Bayer’s collaboration with Evotec, has received both Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA), highlighting its potential as a significant therapeutic option for patients suffering from this condition.

As Bayer progresses with the ASSESS trial, the pharmaceutical company aims to provide a clearer understanding of the safety and efficacy of BAY 3401016, potentially ushering in a new era of treatment for those affected by Alport Syndrome.

For more information on the ASSESS trial, details can be found at www.clinicaltrials.gov.

Bayer, a global leader in life sciences, focuses on healthcare and nutrition, aiming to support major health challenges faced by populations worldwide. With approximately 93,000 employees and a reported revenue of €46.6 billion in fiscal 2024, Bayer continues to invest significantly in research and development, amounting to €6.2 billion.

For additional information about Bayer and its initiatives, visit www.bayer.com.